192 related articles for article (PubMed ID: 23057544)
21. Conference scene: UK pharmacogenetics and stratified medicine network.
Hall I
Pharmacogenomics; 2012 Jan; 13(1):19-20. PubMed ID: 22176620
[TBL] [Abstract][Full Text] [Related]
22. Pharmacogenomics and personalized medicine in clinical practice.
Manolopoulos VG; Dechairo B; Huriez A; Kühn A; Llerena A; van Schaik RH; Yeo KT; Ragia G; Siest G
Pharmacogenomics; 2011 May; 12(5):597-610. PubMed ID: 21619425
[TBL] [Abstract][Full Text] [Related]
23. Indo-Swiss symposium on advances in pharmacogenomic strategies for implementation of personalized medicine.
Xaviar S; Kumar S; Ramasamy K; Chakradhara Rao US
Pharmacogenomics; 2021 Jan; 22(2):67-71. PubMed ID: 33305611
[TBL] [Abstract][Full Text] [Related]
24. Systems medicine, personalized health and therapy.
Siest G; Auffray C; Taniguchi N; Ingelman-Sundberg M; Murray H; Visvikis-Siest S; Ansari M; Marc J; Jacobs P; Meyer U; Van Schaik RH; Müller MM; Wevers RA; Simmaco M; Kussmann M; Manolopoulos VG; Alizadeh BZ; Beastall G; Németh G
Pharmacogenomics; 2015; 16(14):1527-39. PubMed ID: 26401575
[TBL] [Abstract][Full Text] [Related]
25. Challenges and Opportunities for Clinical Pharmacogenetic Research Studies in Resource-limited Settings: Conclusions From the Council for International Organizations of Medical Sciences-Ibero-American Network of Pharmacogenetics and Pharmacogenomics Meeting.
Peñas-LLedó E; Terán E; Sosa-Macías M; Galaviz-Hernández C; Gil JP; Nair S; Diwakar S; Hernández I; Lara-Riegos J; Ramírez-Roa R; Verde I; Tarazona-Santos E; Molina-Guarneros J; Moya G; Rägo L; LLerena A
Clin Ther; 2020 Aug; 42(8):1595-1610.e5. PubMed ID: 32782137
[TBL] [Abstract][Full Text] [Related]
26. Pharmacogenomics in cancer therapy: is host genome variability important?
Petros WP; Evans WE
Trends Pharmacol Sci; 2004 Sep; 25(9):457-64. PubMed ID: 15559247
[TBL] [Abstract][Full Text] [Related]
27. [Personalized drug therapy based on genetics. Possibilities and examples from clinical practice].
Stingl JC; Just KS; Kaumanns K; Schurig-Urbaniak M; Scholl C; von Mallek D; Brockmöller J
Internist (Berl); 2016 Mar; 57(3):289-97. PubMed ID: 26830424
[TBL] [Abstract][Full Text] [Related]
28. New perspectives in personalised medicine for ethnicity in cancer: population pharmacogenomics and pharmacometrics.
Nair S; LLerena A
Drug Metab Pers Ther; 2018 Jun; 33(2):61-64. PubMed ID: 29688886
[No Abstract] [Full Text] [Related]
29. Conference scene: pharmacogenomics: from cell to clinic (part 2).
Siest G; Medeiros R; Melichar B; Stathopoulou M; Van Schaik RH; Cacabelos R; Abt PM; Monteiro C; Gurwitz D; Queiroz J; Mota-Filipe H; Ndiaye NC; Visvikis-Siest S
Pharmacogenomics; 2014 Apr; 15(6):739-44. PubMed ID: 24897282
[TBL] [Abstract][Full Text] [Related]
30. Personalized Medicine: Pharmacogenomics and Drug Development.
Mirsadeghi S; Larijani B
Acta Med Iran; 2017 Mar; 55(3):150-165. PubMed ID: 28282716
[TBL] [Abstract][Full Text] [Related]
31. [Personalized dosing from perspective of pharmacogenomics of drug metabolizing enzymes and transporters].
Zhou Q; Yu LS; Zeng S
Yao Xue Xue Bao; 2017 Jan; 52(1):1-7. PubMed ID: 29911367
[TBL] [Abstract][Full Text] [Related]
32. Enabling personalized cancer medicine decisions: The challenging pharmacological approach of PBPK models for nanomedicine and pharmacogenomics (Review).
Vizirianakis IS; Mystridis GA; Avgoustakis K; Fatouros DG; Spanakis M
Oncol Rep; 2016 Apr; 35(4):1891-904. PubMed ID: 26781205
[TBL] [Abstract][Full Text] [Related]
33. Personalized medicine and economic evaluation in oncology: all theory and no practice?
Garattini L; Curto A; Freemantle N
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):733-8. PubMed ID: 26289733
[TBL] [Abstract][Full Text] [Related]
34. The role of pharmacogenetics and pharmacogenomics in 21st-century medicine: state of the art and new challenges discussed in the VII Conference of the Spanish Pharmacogenetics and Pharmacogenomics Society (SEFF).
Rodriguez-Antona C
Drug Metab Pers Ther; 2016 Mar; 31(1):1-2. PubMed ID: 26641977
[No Abstract] [Full Text] [Related]
35. Pharmacogenetics in cancer therapy - 8 years of experience at the Institute for Oncology and Radiology of Serbia.
Cavic M; Krivokuca A; Boljevic I; Brotto K; Jovanovic K; Tanic M; Filipovic L; Zec M; Malisic E; Jankovic R; Radulovic S
J BUON; 2016; 21(5):1287-1295. PubMed ID: 27837635
[TBL] [Abstract][Full Text] [Related]
36. Pharmacogenomics, Pharmacokinetics, and Pharmacodynamics in the Era of Targeted Therapies.
Calvo E; Walko C; Dees EC; Valenzuela B
Am Soc Clin Oncol Educ Book; 2016; 35():e175-84. PubMed ID: 27249721
[TBL] [Abstract][Full Text] [Related]
37. Translating Knowledge from Research to Outcomes: Pharmacogenomics in the Treatment of HIV/AIDS.
Hewitt JE
J Law Med; 2016; 24(1):166-80. PubMed ID: 30136780
[TBL] [Abstract][Full Text] [Related]
38. Pharmacogenomic Challenges in Cardiovascular Diseases: Examples of Drugs and Considerations for Future Integration in Clinical Practice.
Chatelin J; Stathopoulou MG; Arguinano AA; Xie T; Visvikis-Siest S
Curr Pharm Biotechnol; 2017; 18(3):231-241. PubMed ID: 28117005
[TBL] [Abstract][Full Text] [Related]
39. Third Annual Open Meeting of the UK Pharmacogenomics and Stratified Medicine Network Conference.
Bradshaw EH
Pharmacogenomics; 2015 Jul; 16(8):775-8. PubMed ID: 26067484
[TBL] [Abstract][Full Text] [Related]
40. Response to "personalized medicine, genomics, and pharmacogenomics".
Mayer DK
Clin J Oncol Nurs; 2014 Dec; 18(6):618. PubMed ID: 25427694
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
